Skip to main
ARGX

argenx (ARGX) Stock Forecast & Price Target

argenx (ARGX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 41%
Buy 53%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

argenx is poised for long-term success due to its strong pipeline of potential treatments for rare autoimmune diseases, as seen through the successful FDA approvals and ongoing clinical trials. While facing competition in the market, argenx's solid financial position and continued progress in its various programs suggest potential for future growth and success. However, it is worth noting that as with any drug development company, there is risk involved in clinical trials and potential dilution risk for shareholders in the future.

Bears say

argenx is a biopharmaceutical company that has received FDA approval for its lead product, Vyvgart and Vyvgart Hytrulo, for the treatment of rare autoimmune diseases. Despite a strong pipeline, there are risks to the company's stock and rating, such as potential clinical, regulatory, or commercial failures for its products, efgartigimod and ARGX-117. These risks may hinder the attainment of its price target and rating.

argenx (ARGX) has been analyzed by 17 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 53% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About argenx (ARGX) Forecast

Analysts have given argenx (ARGX) a Buy based on their latest research and market trends.

According to 17 analysts, argenx (ARGX) has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,027.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,027.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

argenx (ARGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.